肝细胞癌组织COPB2基因水平变化及其临床意义探讨

doi:10.3969/j.issn.1672-5069.2021.01.030

实用肝脏病杂志 ›› 2021, Vol. 24 ›› Issue (1): 115-118.doi: 10.3969/j.issn.1672-5069.2021.01.030

肝细胞癌组织COPB2基因水平变化及其临床意义探讨

刘振, 潘光栋, 周峥, 刘强, 梁越, 黄科团, 郝树青, 杨建青

545006 广西壮族自治区柳州市广西医科大学附属柳州市人民医院肝胆胰外科(刘振,潘光栋,周峥,刘强,黄科团,郝树青,杨建青);
病理科(梁越)

出版日期:2021-01-10 发布日期:2021-01-19
通讯作者: 刘振,男,41岁,医学硕士,副主任医师。E-mail:hawk12182020@163.com
通讯作者:杨建青,E-mail:yangjianqing2004@163.com
作者简介:刘振,男,41岁,医学硕士,副主任医师。E-mail:hawk12182020@163.com
基金资助:
广西壮族自治区卫生与计划生育委员会科研课题(编号:Z20170670);柳州市科技局科研计划项目(编号:2018DB20502)

Expression of copb2 gene incancerous tissues in patients with hepatocellular carcinoma and its relationship with prognosis

Liu Zhen,Pan Guangdong,Zhou Zheng,et al

Department of Hepatobiliary and Pancreatic Surgery, People's Hospital Affiliated to Guangxi Medical University,Liuzhou 545006,Guangxi Zhuang Autonomous Region,China

Online:2021-01-10 Published:2021-01-19

摘要/Abstract

摘要： 目的探讨肝细胞癌(HCC)组织衣被蛋白复合体亚基β2(coatomer protein complex subunit beta 2,COPB2)基因水平变化及其临床意义。方法在113例HCC患者,采取肝癌切除术治疗,取癌组织和癌旁肝组织,采用RT-PCR法检测COPB2 mRNA水平,采用Western blot法和免疫组化法检测COPB2蛋白表达水平。建立多变量COX比例风险回归模型分析影响HCC患者预后的独立危险因素。结果 HCC组织和癌旁肝组织COPB2基因mRNA水平分别为1.32±0.40和0.47±0.14,差异具有统计学意义(P=0.013),两者COPB2蛋白相对表达水平分别为1.35±0.56和0.44±0.12,也具有显著性统计学差异(P=0.035);本组癌组织COPB2蛋白高表达45例(39.8%),低表达或阴性68例(60.2%);有无HBV感染、术前血清AFP水平、不同肿瘤结节数目、肿瘤分化程度和有无血管浸润患者癌组织COPB2蛋白表达强度不同(P＜0.05);本组113例患者死亡68例(59.8%),生存时间为(1047.0±167.7) d,中位生存时间1046 d;COPB2蛋白高表达组平均生存时间为(747.3±116.3) d,中位生存时间为610 d,COPB2蛋白低表达组平均生存时间为(1673.7±213.5) d,中位生存时间为1462 d(P=0.001);多因素Cox比例风险回归模型分析结果显示,术前血清AFP水平、血管浸润、肿瘤结节数目和肝癌组织COPB2表达水平是影响 HCC患者总生存时间的独立影响因素(P<0.05)。结论 HCC患者癌组织COPB2过表达可能预示不良预后,该基因及其蛋白表达可能与肿瘤细胞侵袭转移密切相关,COPB2可能成为预警HCC患者不良预后的一个新的分子标志物并可能成为潜在的治疗靶点。

关键词: 肝细胞癌, 衣被蛋白复合体亚基β2, 肿瘤标志物, 预后

Abstract: Objective The aim of this study was to investigate the expression of coatomer protein complex subunit beta 2 (copb2) gene in cancerous tissues in patients with hepatocellular carcinoma (HCC) and its relationship with prognosis. Methods 113 patients with HCC underwent hepatectomy, and the COPB2 mRNA and its protein expression in cancerous and adjacent noncancerous tissues were detected by RT-PCR and Western bloting as well as immunohistochemistry. The multivariate Cox proportional risk regression model was established to analyze the independent risk factors affecting the prognosis of patients with HCC. Results The COPB2 mRNA in cancerous and noncancerous tissues were (1.32±0.40) and (0.47±0.14), significantly different between them(P=0.013), and the COPB2 protein expression were (1.35±0.56) and (0.44±0.12), also significantly different between them(P=0.035); the strong cancerous COPB2 expression was found in 45 patients(39.8%), while the weak or negative expression was found in 68 patients(60.2%); the expression of COPB2 was found much different in patients with or without HBV infection, with different serum AFP levels, different tumor foci, different tumor cell differentiation, and with or without tumor invasion (P＜0.05); 68 patients (59.8%) died in our series at the end of follow-up, with the survival time of (1047.0±167.7) days; the survial time in patients with strong cancerous COPB2 expression was (747.3±116.3) days, much shorter than(1673.7±213.5) days in patients with weak or negative COPB2 expression(P=0.001); the multivariate Cox proportional risk regression model showed that the cancerous COPB2 expression, serum AFP levels, tumor invasion and tumor foci were the independent risk factor for overall survival of patients with HCC.Conclusion The up-regulation of COPB2 expression in cancerous tissues in patients with HCC might hint the bad prognosis after hepatectomy, which warrants further investigation.

Key words: Hepatocellular carcinoma, Coatomer protein complex subunit beta 2, Tumor markers, Prognosis

刘振, 潘光栋, 周峥, 刘强, 梁越, 黄科团, 郝树青, 杨建青. 肝细胞癌组织COPB2基因水平变化及其临床意义探讨[J]. 实用肝脏病杂志, 2021, 24(1): 115-118.

Liu Zhen,Pan Guangdong,Zhou Zheng,et al. Expression of copb2 gene incancerous tissues in patients with hepatocellular carcinoma and its relationship with prognosis[J]. Journal of Practical Hepatology, 2021, 24(1): 115-118.

参考文献

[1] Christodoulou EG, Yang H, Lademann F, et al. Detection of COPB2 as a KRAS synthetic lethal partner through integration of functional genomics screens. Oncotarget, 2017, 8(21):34283-34297.
[2] Bulir DC, Waltho DA, StoneCB, et al. Chlamydia pneumoniae copd translocator protein plays a critical role in type III secretion (T3S) and infection. PLoS One, 2014, 9(6):e99315.
[3] Fields KA, Fischer ER, Mead DJ, et al. Analysis of putative chlamydia trachomatis chaperones Scc2 and Scc3 and their use in the identification of type III secretion substrates. J Bacteriol, 2005, 187(18):6466-6478.
[4] An C, Li H, Zhang X, et al. Silencing of COPB2 inhibits the proliferation of gastric cancer cells and induces apoptosis via suppression of the RTK signaling pathway. Int J Oncol, 2019, 54(4):1195-1208.
[5] Bhandari A, Zheng C, Sindan N, et al. COPB2 is up-regulated in breast cancer and plays a vital role in the metastasis via n-cadherin and vimentin. J Cell Mol Med, 2019, 23(8):5235-5245.
[6] Pu X, Wang J, Li W, et al. COPB2 promotes cell proliferation and tumorigenesis through up-regulating YAP1 expression in lung adenocarcinoma cells. Biomed Pharmacother, 2018, 103:373-380.
[7] Li ZS, Liu CH, Liu Z, et al. Downregulation of COPB2 by RNAi inhibits growth of human cholangiocellular carcinoma cells. Eur Rev Med Pharmacol Sci, 2018, 22(4):985-992.
[8] Zhou Y, Wang X, Huang X, et al. High expression of COPB2 predicts adverse outcomes: a potential therapeutic target for glioma. CNS Neurosci Ther, 2020 ,26(3):309-318.
[9] 代晓楠, 吕金燕, 翁文采, 等. 肝癌组织IFITM3蛋白表达水平及其与肝细胞癌患者手术切除术后肝内肿瘤复发的相关性分析. 实用肝脏病杂志, 2019, 22(1):117-120.
[10] Mak LY, Cruz-Ramón V, Chinchilla-López P, et al. Global epidemiology, prevention, and management of hepatocellular carcinoma. Am Soc Clin Oncol Educ Book, 2018, 23(38):262-279.
[11] Zhang B, Zhang B, Zhang Z, et al. 42,573 cases of hepatectomy in China: a multicenter retrospective investigation. Sci China Life Sci, 2018, 61(6):660-670.
[12] Kalyan A, Nimeiri H, Kulik L. Systemic therapy of hepatocellular carcinoma: current and promising. Clin Liver Dis, 2015 ,19(2):421-432.
[13] Couri T, Pillai A. Goals and targets for personalized therapy for HCC. Hepatol Int, 2019, 13(2):125-137.
[14] Kudo M. Systemic therapy for hepatocellular carcinoma: 2017 update. Oncology, 2017, 93(Suppl 1):135-146.
[15] Li L, Wang H. Heterogeneity of liver cancer and personalized therapy. Cancer Lett, 2016, 379(2):191-197.
[16] Li D, Roberts R. Wd-repeat proteins: structure characteristics, biological function, and their involvement in human diseases. Cell Mol Life Sci, 2001, 58(14):2085-2097.
[17] Chen HL, Li JJ, Jiang F, et al. MicroRNA-4461 derived from bone marrow mesenchymal stem cell exosomes inhibits tumorigenesis by downregulating COPB2 expression in colorectal cancer. Biosci Biotechnol Biochem, 2020, 84(2):338-346.
[18] Sudo H, Tsuji AB, Sugyo A, et al. Knockdown of COPA, identified by loss-of-function screen, induces apoptosis and suppresses tumor growth in mesothelioma mouse mode. Genomics, 2010, 95(4):210-216.
[19] Wang Y, Chai Z, Wang M, et al. COPB2 suppresses cell proliferation and induces cell cycle arrest in human colon cancer by regulating cell cycle-related proteins. Exp Ther Med, 2018, 15(1):777-784.

肝细胞癌组织COPB2基因水平变化及其临床意义探讨

Expression of copb2 gene incancerous tissues in patients with hepatocellular carcinoma and its relationship with prognosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘奇, 郝吉庆. 免疫联合治疗肝细胞癌研究进展[J]. 实用肝脏病杂志, 2021, 24(1): 7-9.
[2]	邢晓燕, 黄良苗, 符爱仙, 李兴钦, 韩向阳. 茵栀黄联合腺苷蛋氨酸治疗妊娠期肝内胆汁淤积症患者疗效观察及其对母婴结局的影响[J]. 实用肝脏病杂志, 2020, 23(5): 670-673.
[3]	王培, 张青, 李颍, 颜学兵, 丁芹. 基于红细胞分布宽度和中性粒细胞/淋巴细胞比值建立慢加急性乙型肝炎肝衰竭患者短期预后预测模型价值研究[J]. 实用肝脏病杂志, 2020, 23(5): 682-686.
[4]	韩鹏伟, 王虎明, 赵天永. AFP阴性原发性肝癌临床特征及预后因素分析[J]. 实用肝脏病杂志, 2020, 23(5): 715-718.
[5]	鲁斌, 程敏. 肝细胞癌患者血清Dickopff 1水平对TACE治疗后预后的影响[J]. 实用肝脏病杂志, 2020, 23(5): 719-722.
[6]	周彬彬, 孙姚晨, 黄海帆, 鲍健. TACE术后肝细胞癌患者功能磁共振成像参数变化研究[J]. 实用肝脏病杂志, 2020, 23(5): 723-726.
[7]	李琛, 阚建英. 供体血清细胞因子水平与肝移植受者术后生存关系探讨[J]. 实用肝脏病杂志, 2020, 23(5): 739-742.
[8]	何文昌, 张克恭, 赵凡惠, 郭芮杉, 高禄化, 黄长形, 王临旭. 290例药物性肝损伤患者临床特征分析^*[J]. 实用肝脏病杂志, 2020, 23(4): 540-543.
[9]	张静, 周新民. 应用重组人血小板生成素减少肝硬化患者术前血小板输注疗效初步研究^*[J]. 实用肝脏病杂志, 2020, 23(4): 552-555.
[10]	顾世玉, 秦文举, 高建芝, 薛明辉. 肝细胞癌癌组织Hic-5和COL1A1表达及其对术后生存的预测价值^*[J]. 实用肝脏病杂志, 2020, 23(4): 576-580.
[11]	冯涛, 胡伟, 滕步伟, 李伟. ALBI联合剩余肝体积对HBV相关原发性肝癌患者肝切除术后肝衰竭发生的预测价值^*[J]. 实用肝脏病杂志, 2020, 23(4): 585-588.
[12]	罗凌,邓万玉,彭蕾,张振华,邹桂舟. 肝衰竭患者血浆置换治疗后血清胆红素和凝血酶原活动度变化规律浅探[J]. 实用肝脏病杂志, 2020, 23(3): 384-387.
[13]	崔喆,徐兰. 基于多数据库分析肝细胞癌组织FAM49B基因水平及其临床意义[J]. 实用肝脏病杂志, 2020, 23(3): 413-418.
[14]	徐学清,李炳超,冯铠莉. CT增强纹理技术对TACE治疗的原发性肝癌患者术后肿瘤短期进展的预测价值[J]. 实用肝脏病杂志, 2020, 23(3): 423-426.
[15]	王亮亮,杨波,张卫国. 荧光腹腔镜肝切除术与常规腹腔镜肝切除术治疗HCC患者效果比较[J]. 实用肝脏病杂志, 2020, 23(3): 427-430.